clinical trial · NCT07296809
SKB500 Combinations in Patients With Small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·phase2·recruiting·n = 80
Small Cell Lung CancerSKB500 Powder for InjectionKL-A167 InjectionCarboplatin InjectionEtoposide Injection
brief summary
The purpose of this study is to assess the safety, tolerability and preliminary antitumor activity of SKB500 combinations in patients with small cell lung cancer. The study is divided into two parts. Part 1 will be the safety run-in phase, and Part 2 will be the cohort expansion phase.
started
Jan 30, 2026
primary completion
Dec 31, 2028
completion
Dec 31, 2029
last updated
Apr 2, 2026
official title
A Phase II, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of SKB500 Combinations in Patients With Small Cell Lung Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol